Annual SG&A
$131.88 M
-$13.52 M-9.30%
31 December 2023
Summary:
Karyopharm Therapeutics annual selling, general & administrative expenses is currently $131.88 million, with the most recent change of -$13.52 million (-9.30%) on 31 December 2023. During the last 3 years, it has fallen by -$11.96 million (-8.32%). KPTI annual SG&A is now -9.30% below its all-time high of $145.40 million, reached on 31 December 2022.KPTI Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$27.63 M
-$3.44 M-11.07%
30 September 2024
Summary:
Karyopharm Therapeutics quarterly selling, general & administrative expenses is currently $27.63 million, with the most recent change of -$3.44 million (-11.07%) on 30 September 2024. Over the past year, it has dropped by -$3.06 million (-9.96%). KPTI quarterly SG&A is now -28.72% below its all-time high of $38.77 million, reached on 31 March 2022.KPTI Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$6.04 B
-$87.48 M-1.47%
30 September 2024
Summary:
Karyopharm Therapeutics TTM selling, general & administrative expenses is currently -$6.04 billion, with the most recent change of -$87.48 million (-1.47%) on 30 September 2024. Over the past year, it has dropped by -$6.18 billion (-4683.47%). KPTI TTM SG&A is now -21019.16% below its all-time high of $145.77 million, reached on 30 June 2022.KPTI TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KPTI Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -10.0% | -4683.5% |
| 3 y3 years | -8.3% | -20.1% | -4302.2% |
| 5 y5 years | +25.1% | -2.7% | -5833.9% |
KPTI Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -9.3% | +4.3% | -28.7% | at low | -32.4% | at low |
| 5 y | 5 years | -9.3% | +170.0% | -28.7% | +9.4% | -100.0% | at low |
| alltime | all time | -9.3% | +7067.4% | -28.7% | +4467.3% | <-9999.0% | at low |
Karyopharm Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $27.63 M(-11.1%) | $118.94 M(-2.6%) |
| June 2024 | - | $31.07 M(+5.1%) | $122.11 M(-2.7%) |
| Mar 2024 | - | $29.55 M(-3.7%) | $125.52 M(-4.8%) |
| Dec 2023 | $131.88 M(-9.3%) | $30.69 M(-0.4%) | $131.88 M(-2.9%) |
| Sept 2023 | - | $30.80 M(-10.7%) | $135.84 M(-2.7%) |
| June 2023 | - | $34.48 M(-4.0%) | $139.68 M(-2.0%) |
| Mar 2023 | - | $35.91 M(+3.6%) | $142.54 M(-2.0%) |
| Dec 2022 | $145.40 M(+1.1%) | $34.65 M(+0.0%) | $145.40 M(+0.1%) |
| Sept 2022 | - | $34.65 M(-7.2%) | $145.31 M(-0.3%) |
| June 2022 | - | $37.34 M(-3.7%) | $145.77 M(+0.6%) |
| Mar 2022 | - | $38.77 M(+12.2%) | $144.96 M(+0.8%) |
| Dec 2021 | $143.85 M(+13.8%) | $34.56 M(-1.5%) | $143.85 M(+0.4%) |
| Sept 2021 | - | $35.10 M(-3.9%) | $143.21 M(+3.0%) |
| June 2021 | - | $36.53 M(-3.0%) | $139.08 M(+4.3%) |
| Mar 2021 | - | $37.65 M(+11.0%) | $133.39 M(+5.5%) |
| Dec 2020 | $126.42 M(+19.9%) | $33.93 M(+9.6%) | $126.42 M(+4.6%) |
| Sept 2020 | - | $30.97 M(+0.4%) | $120.88 M(+4.9%) |
| June 2020 | - | $30.84 M(+0.5%) | $115.18 M(+5.7%) |
| Mar 2020 | - | $30.68 M(+8.1%) | $109.00 M(+3.4%) |
| Dec 2019 | $105.42 M(+115.8%) | $28.39 M(+12.4%) | $105.42 M(+10.0%) |
| Sept 2019 | - | $25.27 M(+2.5%) | $95.80 M(+14.7%) |
| June 2019 | - | $24.66 M(-9.0%) | $83.50 M(+22.2%) |
| Mar 2019 | - | $27.10 M(+44.4%) | $68.33 M(+39.9%) |
| Dec 2018 | $48.85 M | $18.77 M(+44.8%) | $48.85 M(+34.8%) |
| Sept 2018 | - | $12.97 M(+36.6%) | $36.23 M(+24.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | $9.49 M(+24.5%) | $29.08 M(+10.9%) |
| Mar 2018 | - | $7.62 M(+23.9%) | $26.23 M(+5.5%) |
| Dec 2017 | $24.87 M(+3.9%) | $6.15 M(+5.8%) | $24.87 M(-1.5%) |
| Sept 2017 | - | $5.82 M(-12.3%) | $25.26 M(-0.3%) |
| June 2017 | - | $6.63 M(+5.9%) | $25.34 M(+2.8%) |
| Mar 2017 | - | $6.26 M(-4.2%) | $24.66 M(+3.0%) |
| Dec 2016 | $23.95 M(+11.0%) | $6.54 M(+10.9%) | $23.95 M(+5.6%) |
| Sept 2016 | - | $5.90 M(-1.0%) | $22.67 M(+5.3%) |
| June 2016 | - | $5.96 M(+7.2%) | $21.54 M(-0.9%) |
| Mar 2016 | - | $5.55 M(+5.5%) | $21.74 M(+0.7%) |
| Dec 2015 | $21.58 M(+35.3%) | $5.26 M(+10.5%) | $21.58 M(-2.9%) |
| Sept 2015 | - | $4.76 M(-22.7%) | $22.24 M(+4.5%) |
| June 2015 | - | $6.16 M(+14.0%) | $21.29 M(+15.4%) |
| Mar 2015 | - | $5.40 M(-8.8%) | $18.44 M(+15.6%) |
| Dec 2014 | $15.95 M(+171.0%) | $5.92 M(+55.2%) | $15.95 M(+27.5%) |
| Sept 2014 | - | $3.81 M(+15.2%) | $12.51 M(+21.7%) |
| June 2014 | - | $3.31 M(+14.0%) | $10.28 M(+29.9%) |
| Mar 2014 | - | $2.90 M(+17.1%) | $7.91 M(+34.4%) |
| Dec 2013 | $5.88 M(+142.3%) | $2.48 M(+56.7%) | $5.88 M(+46.8%) |
| Sept 2013 | - | $1.58 M(+67.9%) | $4.01 M(+29.4%) |
| June 2013 | - | $943.00 K(+7.3%) | $3.10 M(+43.7%) |
| Mar 2013 | - | $879.00 K(+45.3%) | $2.16 M(+68.8%) |
| Dec 2012 | $2.43 M(+32.0%) | $605.00 K(-10.0%) | $1.28 M(+90.0%) |
| Sept 2012 | - | $672.00 K | $672.00 K |
| Dec 2011 | $1.84 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly SG&A year-on-year change?
- What is Karyopharm Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM SG&A year-on-year change?
What is Karyopharm Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of KPTI is $131.88 M
What is the all time high annual SG&A for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual selling, general & administrative expenses is $145.40 M
What is Karyopharm Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of KPTI is $27.63 M
What is the all time high quarterly SG&A for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly selling, general & administrative expenses is $38.77 M
What is Karyopharm Therapeutics quarterly SG&A year-on-year change?
Over the past year, KPTI quarterly selling, general & administrative expenses has changed by -$3.06 M (-9.96%)
What is Karyopharm Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of KPTI is -$6.04 B
What is the all time high TTM SG&A for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM selling, general & administrative expenses is $145.77 M
What is Karyopharm Therapeutics TTM SG&A year-on-year change?
Over the past year, KPTI TTM selling, general & administrative expenses has changed by -$6.18 B (-4683.47%)